MedKoo Cat#: 206517 | Name: FT-1101 free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FT-1101 is an orally bioavailable, potent and selective BET inhibitor. FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.

Chemical Structure

FT-1101 free base
FT-1101 free base
CAS#1776060-36-6 (free base)

Theoretical Analysis

MedKoo Cat#: 206517

Name: FT-1101 free base

CAS#: 1776060-36-6 (free base)

Chemical Formula: C26H34N4O2

Exact Mass: 434.2682

Molecular Weight: 434.58

Elemental Analysis: C, 71.86; H, 7.89; N, 12.89; O, 7.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1776060-36-6 (free base) 2407727-80-2 (HCl) 2407727-84-6 (2HCl) 2407727-92-6 (maleate),2407727-96-0 (citrate) 2407727-99-3 (fumarate) 2407728-02-1 (tartrate) 2407728-28-1 (mesylate) 2407728-32-7 (besylate)
Synonym
FT-1101; FT 1101; FT1101; FT-1101 free base;
IUPAC/Chemical Name
[(2S)-5-(Cyclobutyloxy)-3,4-dihydro-2-methyl-6-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-1(2H)-quinolinyl]cyclopropylmethanone
InChi Key
WANNIOQKRZPMMR-KRWDZBQOSA-N
InChi Code
InChI=1S/C26H34N4O2/c1-17-5-8-23-24(30(17)26(31)18-6-7-18)10-9-22(25(23)32-21-3-2-4-21)19-15-28-29(16-19)20-11-13-27-14-12-20/h9-10,15-18,20-21,27H,2-8,11-14H2,1H3/t17-/m0/s1
SMILES Code
O=C(N1[C@@H](C)CCC2=C1C=CC(C3=CN(C4CCNCC4)N=C3)=C2OC5CCC5)C6CC6
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 434.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Chuang SH, Lee YE, Huang LYL, Chen CK, Lai CL, Lin YH, Yang JY, Yang SC, Chang LH, Chen CH, Liu CW, Lin HS, Lee YR, Huang KP, Fu KC, Jen HM, Lai JY, Jian PS, Wang YC, Hsueh WY, Tsai PY, Hong WH, Chang CC, Wu DZ, Wu J, Chen MH, Yu KM, Chern CY, Chang JM, Lau JYN, Huang JJ. Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy. Eur J Med Chem. 2020 Apr 1;191:112118. doi: 10.1016/j.ejmech.2020.112118. Epub 2020 Feb 7. PMID: 32113126.